Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to -$2.1 million.

  • 60 Degrees Pharmaceuticals' Free Cash Flow fell 2501.94% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.9 million, marking a year-over-year decrease of 6193.25%. This contributed to the annual value of -$5.8 million for FY2024, which is 2502.6% down from last year.
  • 60 Degrees Pharmaceuticals' Free Cash Flow amounted to -$2.1 million in Q3 2025, which was down 2501.94% from -$1.5 million recorded in Q2 2025.
  • Over the past 5 years, 60 Degrees Pharmaceuticals' Free Cash Flow peaked at -$97552.0 during Q4 2022, and registered a low of -$3.7 million during Q3 2023.
  • For the 4-year period, 60 Degrees Pharmaceuticals' Free Cash Flow averaged around -$1.2 million, with its median value being -$1.3 million (2024).
  • Over the last 5 years, 60 Degrees Pharmaceuticals' Free Cash Flow had its largest YoY gain of 5467.3% in 2024, and its largest YoY loss of 127126.01% in 2024.
  • 60 Degrees Pharmaceuticals' Free Cash Flow (Quarter) stood at -$97552.0 in 2022, then dropped by 22.47% to -$119468.0 in 2023, then plummeted by 1271.26% to -$1.6 million in 2024, then dropped by 29.35% to -$2.1 million in 2025.
  • Its Free Cash Flow was -$2.1 million in Q3 2025, compared to -$1.5 million in Q2 2025 and -$1.6 million in Q1 2025.